PMID- 28092162
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20171116
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 95
IP  - 3
DP  - 2017 Mar
TI  - Clinical use of high mobility group box 1 and the receptor for advanced glycation 
      end products in the prognosis and risk stratification of heart failure: a 
      literature review.
PG  - 253-259
LID - 10.1139/cjpp-2016-0299 [doi]
AB  - Heart failure (HF) is a clinical syndrome that represents the end stage of heart 
      disease and remains the leading cause of morbidity and mortality worldwide. As 
      heart failure mortality rates remain elevated, additional biomarkers that 
      facilitate early detection or risk stratification in HF is of particularly great 
      interest. High mobility group box 1 (HMGB1) and receptor for advanced glycation 
      end products (RAGE) cause the activation of intracellular signaling, gene 
      expression, and production of inflammatory cytokines and have been linked to many 
      inflammatory disease states such as diabetes mellitus and atherosclerosis. Few 
      studies have investigated their role in the pathophysiology of HF and any 
      significant correlation remains uncertain. Review of the available literature 
      discussing HMGB1 and RAGE clinical values as independent prognostic variables in 
      HF resulted in the inclusion of 11 studies, which enrolled a total of 2025 heart 
      failure patients. Overall, the data suggests a statistically significant positive 
      correlation between RAGE and HF, with increasing RAGE levels associated with 
      increasing New York Heart Association (NYHA) functional class of heart failure. 
      HMGB1 correlations were not as extensively studied, but there is evidence that 
      both HMGB1 and RAGE have a definite potential as biomarkers for the prognosis and 
      risk stratification of HF patients.
FAU - Marsh, Amanda M
AU  - Marsh AM
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
FAU - Nguyen, Austin Huy
AU  - Nguyen AH
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
FAU - Parker, Taylor M
AU  - Parker TM
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
FAU - Agrawal, Devendra K
AU  - Agrawal DK
AD  - Department of Clinical and Translational Science, Creighton University School of 
      Medicine, Omaha, NE, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161130
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (AGER protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
RN  - 0 (Receptor for Advanced Glycation End Products)
SB  - IM
MH  - Biomarkers/metabolism
MH  - HMGB1 Protein/*metabolism
MH  - Heart Failure/diagnosis/*metabolism/physiopathology/therapy
MH  - Humans
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor for Advanced Glycation End Products/*metabolism
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Up-Regulation
OTO - NOTNLM
OT  - HMGB1
OT  - RAGE
OT  - biomarker
OT  - biomarqueur
OT  - heart failure
OT  - high mobility group box 1
OT  - insuffisance cardiaque
OT  - prognosis
OT  - pronostic
OT  - receptor for advanced glycation end products
OT  - recepteur des produits finaux de glycation avancee
OT  - << high mobility group box 1 >>
EDAT- 2017/01/17 06:00
MHDA- 2017/03/23 06:00
CRDT- 2017/01/17 06:00
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
PHST- 2017/01/17 06:00 [entrez]
AID - 10.1139/cjpp-2016-0299 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2017 Mar;95(3):253-259. doi: 10.1139/cjpp-2016-0299. 
      Epub 2016 Nov 30.